Beth Israel Deaconess Medical Center, Inc.

Date of Award

11.05.2020

Program

Therapeutics

Amount

$2,958,404.00

Term of Grant

60 months

Project Title

Proactive optimization of infliximab using a pharmacokinetic dashboard versus standard of care in patients with Crohn's disease: The OPTIMIZE Trial

Project Description

IFX is one of the most effective therapies for CD patients, however dosing challenges currently limit its effectiveness. If successful, this grant will confirm a new treatment paradigm that will allow patients and physicians to personalize and optimize the efficacy and safety of IFX dosing by avoiding the negative effects of being on an additional immunomodulator.